Your session is about to expire
← Back to Search
Descartes-08 for Lupus (SLE-001 Trial)
SLE-001 Trial Summary
"This trial will test the safety and effectiveness of Descartes-08 CAR T-cells in patients with Systemic Lupus Erythematosus (SLE)."
SLE-001 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSLE-001 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.SLE-001 Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are potential candidates still eligible to participate in this ongoing clinical trial?
"Indeed, information on clinicaltrials.gov indicates that this investigation is currently enrolling subjects. The trial was initially posted on February 12th, 2024 and most recently revised on February 27th, 2024. Specifically, the study aims to recruit 30 participants from a single site."
What is the current number of individuals involved in this research endeavor?
"Indeed, the information available on clinicaltrials.gov highlights that this investigation is actively seeking volunteers. The trial was initially listed on February 12, 2024, and was most recently updated on February 27, 2024. This study aims to enroll 30 participants at a single designated site."
Has Descartes-08 been granted approval by the FDA?
"In this Phase 2 trial, Descartes-08 scored a 2 for safety based on current data available. Efficacy data is still pending at this stage of evaluation."
Share this study with friends
Copy Link
Messenger